Wellington Management Group
SWTX

Wellington Management Group’s SpringWorks Therapeutics SWTX Stock Holding History

Wellington Management Group’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,460
Closed -$1.34M – 2105
2025
Q2 		$1.34M Sell
28,460
-2,103
-7% -$93.6K ﹤0.01% 1669
2025
Q1 		$1.35M Sell
30,563
-618
-2% -$28.4K ﹤0.01% 1638
2024
Q4 		$1.13M Sell
31,181
-3,813
-11% -$133K ﹤0.01% 1696
2024
Q3 		$1.12M Buy
34,994
+1,853
+6% +$69.2K ﹤0.01% 1688
2024
Q2 		$1.25M Buy
33,141
+5,087
+18% +$214K ﹤0.01% 1619
2024
Q1 		$1.38M Buy
28,054
+6,887
+33% +$318K ﹤0.01% 1610
2023
Q4 		$773K Buy
+21,167
New +$552K ﹤0.01% 1663
2019
Q4 		– Sell
-70,577
Closed -$1.53M – 2117
2019
Q3 		$1.53M Buy
+70,577
New +$1.67M ﹤0.01% 1650

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Wellington Management Group's SWTX Position: Q3 2025 in Review

Wellington Management Group sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 28,460 shares — an estimated $1.34M sold.

Wellington Management Group first reported a position in SWTX in Q3 2019 and held it in 8 quarters. The position peaked at $1.53M in Q3 2019. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Wellington Management Group reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wellington Management Group sold 28,460 SpringWorks Therapeutics shares in Q3 2025, an estimated $1.34M.
  • Wellington Management Group first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 8 quarters.
  • Wellington Management Group's SpringWorks Therapeutics position peaked at $1.53M in Q3 2019.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Wellington Management Group's 13F filing for Q3 2025, filed 14 Nov 2025.